2024 Year In Review | Page 21

Targeting PD ’ s Underlying Biology

Therapies that target the disease ’ s molecular underpinnings hold potential to slow , stop , reverse or even prevent PD altogether . While none are yet approved , several show promise .
Alpha-synuclein
The pipeline holds at least 15 drugs that represent a range of approaches seeking to target the production , spread or clearance of PD-related alpha-synuclein clumps in the nervous system . Leading programs include Annovis ’ s oral drug buntanetap ,
How MJFF Bolsters the Parkinson ’ s Treatment Pipeline
Funding to de-risk and accelerate key preclinical and clinical development steps
Data , biosamples and other MJFFdistributed resources
Clinical trial protocol input and recruitment strategies
Endpoint consensus and regulatory paths
Patient lived experience and preferences insight
Research and drug development workshops and consortia
18